Cargando…
Glomerular diseases after immune checkpoint inhibitors use: What do We know so far?
The research and application of immune checkpoint inhibitors (ICIs) have enormously promoted the progression of tumor treatment. Gradual implementation of ICIs in clinical practice is largely limited as they exert uncontrolled collateral effects on the immune system, such as immune-related adverse e...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704066/ https://www.ncbi.nlm.nih.gov/pubmed/36420664 http://dx.doi.org/10.1080/0886022X.2022.2147439 |